Cytori Therapeutics, Inc. (CYTX) Reports In-Line Q1 Loss of 14c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Nasdaq hits record high after softer jobs data cuts rate-hike bets
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
Roth Keeps Cytori Therapeutics (CYTX) at 'Buy'; Still Encouraged by Streamlining Efforts
May 13, 2014 9:20 AM EDTRoth Capital affirms Cytori Therapeutics (Nasdaq: CYTX) at Buy with a price target of $10 following Q1 results.
Analyst Joseph Pantginis noted that Cytori posted Q1 loss of $.14 per share, flat with consensus views. Revs of $1.43 million compared with the firm's expectation for $2.7 million.
Pantginis commented, We are encouraged by Cytori's continued streamlining of efforts based on three main fronts, 1) managerial, 2) commercial and, importantly, 3) clinical progress. Primary focus is... More
Cytori Therapeutics (CYTX) Files $100M Mixed Shelf
May 12, 2014 8:00 AM EDTCytori Therapeutics, Inc. (Nasdaq: CYTX) filed a regisration with the U.S. SEC to sell, from time to time, up to $100 million of , Common Stock, Preferred Stock, Debt Securities, Warrants, Units, or any combination thereof.
... More